Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,190.00 at BMO Capital Markets

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective reduced by BMO Capital Markets from $1,300.00 to $1,190.00 in a report released on Friday morning, Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on REGN. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. TD Cowen upped their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Truist Financial decreased their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a report on Friday. Finally, Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $1,090.24.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded up $5.40 during mid-day trading on Friday, hitting $843.60. The company had a trading volume of 1,087,285 shares, compared to its average volume of 768,492. The firm has a market cap of $93.00 billion, a PE ratio of 20.88, a price-to-earnings-growth ratio of 2.88 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.62 and a current ratio of 5.99. Regeneron Pharmaceuticals has a 12 month low of $783.57 and a 12 month high of $1,211.20. The stock’s fifty day moving average price is $1,058.43 and its two-hundred day moving average price is $1,038.87.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the previous year, the firm posted $8.79 earnings per share. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals will post 37.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, VP Jason Pitofsky sold 487 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors have recently bought and sold shares of REGN. Sachetta LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $26,000. Crewe Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $28,000. Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $33,000. Finally, Family Firm Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $33,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.